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(composite: any DVT, non-fatal PE, all-cause mortality) by 49%
and symptomatic VTE by 66% versus enoxaparin. A cost–utility
model (health care perspective) assessed the cost-effectiveness
over ﬁve years following TKR of rivaroxaban versus enoxaparin
in the UK and Spain, two large European countries with different
approaches to post-surgical prophylaxis and patient manage-
ment. The model was populated using RECORD3 data. Pub-
lished epidemiological and clinical data estimated risks of VTE
and post-thrombotic syndrome beyond the trial period. Costs
were derived from published local sources and expressed in
pounds (£) for the UK and euros (€) for Spain. Utilities were
taken from a systematic literature review. Potential savings from
oral administration were included in the UK analysis only, as in
Spain, drug administration costs are included in hospitalisation
charges. RESULTS: The model showed rivaroxaban produced
improved health outcomes and cost savings versus enoxaparin in
the UK and Spain (dominance). Improved health outcomes were
similar across both countries, while rivaroxaban produced cost
savings of £89.15 per patient in the UK and €144.93 in Spain.
Savings were driven by reduced costs of treating symptomatic
VTE and associated long term complications, as well as oral
outpatient administration in the UK. In both countries, pro-
babilistic sensitivity analyses showed rivaroxaban maintained
dominance versus enoxaparin in more than 99% of cases.
CONCLUSIONS: Rivaroxaban is cost-effective following TKR
within the different health care systems of both these two major
European countries.
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OBJECTIVES: Assess cost-effectiveness of 35 days rivaroxaban,
an oral direct Factor Xa inhibitor, versus 12 days and 35 days
subcutaneous enoxaparin for prevention of venous throm-
boembolism (VTE) following total hip replacement (THR).
METHODS: Rivaroxaban regimens were compared with dif-
ferent enoxaparin regimens following THR in two large ran-
domized controlled trials. RECORD1 compared 35 days
prophylaxis with rivaroxaban or enoxaparin, while RECORD2
compared 35 days rivaroxaban with 12 days enoxaparin. While
the ACCP and NICE recommend up to 35 days prophylaxis in
higher-risk patients after THR, a shorter duration is often used
in the UK and elsewhere. In RECORD1, rivaroxaban reduced
total VTE (composite: any DVT, non-fatal PE, all-cause mor-
tality) by 70% versus enoxaparin after 35 days prophylaxis,
although the reduction in symptomatic VTE with rivaroxaban
was not statistically signiﬁcant. In RECORD2, rivaroxaban
reduced total VTE by 79% and symptomatic VTE by 80%
versus 12 days enoxaparin. A cost–utility model (health care
perspective) assessed cost-effectiveness of rivaroxaban versus
both durations of enoxaparin over the ﬁve years following
surgery. The model was populated by RECORD1-2 data while
published epidemiological and clinical data estimated risks of
VTE and post-thrombotic syndrome beyond the trial period.
Costs (2008 pounds [£]) were derived from published sources.
Utilities were taken from a systematic literature review. Poten-
tial savings associated with administration and monitoring were
also included. RESULTS: Thirty-ﬁve days rivaroxaban domi-
nated 35 days enoxaparin, yielding improved health outcomes
(QALYs) and savings of £67.82 per patient. Savings were
driven mainly by reduced outpatient administration costs.
Rivaroxaban also dominated 12 days enoxaparin, with a
QALY gain of 0.022 and savings of £22.38. Probabilistic
sensitivity analyses showed dominance in 98% of cases versus
35 days enoxaparin and 55% versus 12 days enoxaparin.
CONCLUSIONS: Rivaroxaban is cost-effective versus both
12 and 35 days enoxaparin, for prevention of VTE following
THR in the UK.
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OBJECTIVES: Assess economic impact of rivaroxaban, an oral
direct Factor Xa inhibitor, in VTE prevention following total hip
and total knee replacement (THR/TKR). METHODS: Rivaroxa-
ban regimens were compared with enoxaparin regimens for VTE
prevention in three large randomized controlled trials. For THR,
35 days rivaroxaban was compared with 35 days enoxaparin
(RECORD1), or 12 days enoxaparin (RECORD2). RECORD3
compared rivaroxaban and enoxaparin for 12 days following
TKR. Rivaroxaban reduced total VTE (composite: any DVT,
non-fatal PE, all-cause mortality) following THR by 70% versus
35 days enoxaparin and 79% versus 12 days enoxaparin. Fol-
lowing TKR, rivaroxaban reduced total VTE by 49% versus
enoxaparin. Bleeding was similar with both agents. An economic
model (health care perspective) assessed clinical and economic
consequences of rivaroxaban versus enoxaparin for ﬁve years
following surgery. The model was populated using RECORD
1–3 data and calculated outcomes for total VTE and symptom-
atic VTE. Cost results for the latter are presented here. Incidences
for VTE and post-thrombotic syndrome after the trials were
estimated from published data. Costs, (2008 euros [€]), were
derived from published Italian sources. As the Italian rivaroxa-
ban price is not published, rivaroxaban and enoxaparin costs
were excluded. RECORD 1–3 data were combined to estimate
costs and consequences of rivaroxaban versus enoxaparin for
THR/TKR. RESULTS: Overall improvement in outcomes with
rivaroxaban following THR and TKR was 0.021 symptomatic
VTE events per patient undergoing surgery; non-drug costs were
reduced by €81.32. These were consistent with individual THR
and TKR results when the RECORD trials were analysed sepa-
rately. In 2004, 96,000 THR and TKR were performed in Italy.
Rivaroxaban could yield total annual non-drug cost savings of
approximately €7.6 million. CONCLUSIONS: Rivaroxaban
thromboprophylaxis following THR or TKR may improve
health outcomes and reduce non-drug costs versus existing
approaches. Hence rivaroxaban may represent a more efﬁcient
approach to VTE prophylaxis in Italy.
PHC11
THE BURDEN OF ADHESIOLYSIS DURING LAPAROSCOPIC
GYNECOLOGICAL SURGERY
Crowe AM1, Knight AD1, Krishnan S2
1Corvus Communications Limited, Buxted, UK, 2Baxter BioSurgery,
Westlake Village, CA, USA
OBJECTIVES: Previous European research has shown that lap-
aroscopic surgery is frequently complicated by the need for adhe-
siolysis due to adhesions caused by previous surgery. In Europe
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